Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe - Université de Lorraine Access content directly
Journal Articles Crohn's & Colitis 360 Year : 2022

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe

Lynn Huynh
Steve Hass
  • Function : Author
Mei Sheng Duh
  • Function : Author
Heather Sipsma
  • Function : Author
Mu Cheng
  • Function : Author
Angie Lax
  • Function : Author
Arpita Nag
  • Function : Author

Abstract

Abstract Background With many options available for treating inflammatory bowel disease (IBD) in Europe, this study sought to characterize physician treatment preferences and real-world treatment patterns in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). Methods This was a retrospective, noninterventional, physician-administered study. Gastroenterologists and general practitioners (n = 348) in France, Germany, and the United Kingdom provided information on treatment preferences and extracted information from records of patients with moderate-to-severe UC (n = 587) or CD (n = 417) who had received biologic, biosimilar or Janus kinase inhibitor therapies (2014–2019) and had IBD-related medical history available 6 months before and after treatment initiation. Results Physicians largely preferred infliximab and adalimumab or their biosimilars as first-line therapy for UC (originators, 65.8%; biosimilars, 26.1%) and CD (originators, 61.8%; biosimilars, 30.5%). Effectiveness was the most cited reason for treatment preference (92%–93% of physicians). Three-quarters of patients (UC, 75.8%; CD, 73.6%) received infliximab or adalimumab originators in the first line, with more patients receiving infliximab biosimilars than adalimumab biosimilars (12.4%–12.5% and 0.5%–4.1%, respectively, across UC and CD). Persistence was longer for first-line infliximab than adalimumab (UC, 26.6 vs 21.2 months; CD, 31.2 vs 26.7 months) and was generally shorter for their respective biosimilars. Nonbiologic treatments were used in combination with biologics in 14.1% (UC) and 11.5% (CD) of patients. Most patients received 1 biologic therapy (UC, 90.6%; CD, 83.2%); only 9.4% (UC) and 16.8% (CD) received a second biologic. Conclusions Infliximab and adalimumab originators dominated first-line biologic therapy for moderate-to-severe UC and CD. Understanding real-world treatment patterns can help assess new treatment uptake and suggest opportunities for improving treatment.

Dates and versions

hal-04168363 , version 1 (21-07-2023)

Identifiers

Cite

Lynn Huynh, Steve Hass, Laurent Peyrin-Biroulet, Mei Sheng Duh, Heather Sipsma, et al.. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe. Crohn's & Colitis 360, 2022, 4 (1), pp.otac001. ⟨10.1093/crocol/otac001⟩. ⟨hal-04168363⟩

Collections

UNIV-LORRAINE
7 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More